Clinical trial · Observational
Financial Toxicity in Patients With Resected Soft Tissue and Bone Sarcomas
NCT07215611CI-TRIAL-00109936recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 12, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260912-000001
Summary
Brief summary (as posted)
To learn about the financial stress patients undergoing surgery to treat orthopedic cancer experience because of the costs of cancer care, and to learn about the effects of financial stress on participants quality of life.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Sarcomas | Bone Sarcoma | ONTOLOGY_EXACT | 0.98 |
| Financial Toxicity | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| data collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Questionnaires
- timeFrame
- Through study completion; an average of 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Participants who are seen preoperatively at our institution before surgery for primary malignant bone tumor or primary malignant soft tissue tumor will be identified. * Adult orthopedic oncology patients. Stratified by diagnosis of primary malignant bone tumor and primary malignant soft tissue tumor. Exclusion Criteria • Non-English subjects will not be recruited. Subjects are required to be able to read/write in English.
References
Publications (0)
Data not yet available
No reference posted for this study.